CARES Act Submission Assistance
CARES Act Submission Assistance:In order to comply with CARES Act Section 510(j)(3), pharmaceutical businesses are required to use the CDER NextGen portal to submit to the USFDA the manufacturing and distribution details of their medicines. This reporting comprises comprehensive CSV submissions that cover a range of drug categories, including active pharmaceutical ingredients (API) and formulations (both prescription and over-the-counter).
In CARES Act a 10-digit National Drug Code (NDC) number for each product, the Data Universal Numbering System (DUNS) number, the month-by-month quantity sent to the USA, and the overall quantity for each reporting period are among the fields that must be included in the needed CSV file. The NextGen CDER portal is used to validate these submissions, guaranteeing their accuracy and adherence to legal specifications.
One of the main aspects of the CARES Act in terms of FDA regulation is the streamlining of drug-related processes and better tracking of drug products, especially to ensure they’re accessible in emergency situations.
The Act included provisions to encourage the development of generic and biosimilar drugs, which can be crucial during emergencies. By making it easier for these alternatives to enter the market, the government aimed to enhance the accessibility and affordability of drugs, particularly during emergencies when access to brand-name drugs may be limited.
The CARES Act also sought to increase the FDA’s ability to gather real-time data from manufacturers, distributors, and other stakeholders to better monitor the availability of critical drugs. This was done to help predict shortages and address them proactively.
As required by section 510(j)(3) of the FD&C Act, Masuu US Agent assists pharmaceutical businesses in completing CARES reporting to the USFDA. The amounts of each mentioned medication that have been produced, prepared, distributed, compounded, or processed for commercial use must be reported.
The services offered by Masuu US Agent include ensuring timely and accurate submissions to support compliance with the CARES Act requirements, validating the data to satisfy USFDA standards, and preparing the required data in the appropriate CSV format.
Frequently Asked Questions
CARES Act reporting under Section 510(j)(3) of the FD&C Act requires applicable pharmaceutical companies to provide FDA with information about the manufacturing, preparation, processing, and distribution of certain drugs. The reporting helps FDA monitor drug supply and availability.
CARES-related reporting can cover active pharmaceutical ingredients (APIs) and finished drug formulations, including applicable prescription and over-the-counter (OTC) products. Companies should determine their reporting obligations based on the products and activities covered by FDA requirements.
The submission may require information such as the 10-digit NDC, DUNS number, monthly quantity distributed to the United States, and total quantity for the applicable reporting period. Accurate and complete data is important for successful submission.
The NDC provides a standardized identifier for the drug product being reported. Including the appropriate 10-digit NDC helps FDA accurately identify and track the reported product and its associated distribution information.
The DUNS number helps identify the company or facility associated with the reported drug information. Maintaining accurate DUNS information helps ensure consistency across FDA regulatory records and submissions.
The CDER NextGen portal is used for applicable electronic CARES reporting and submission activities. Companies can submit the required data in the specified format, allowing the information to be validated against applicable FDA requirements.
Companies may need to report the month-by-month quantities of applicable drugs distributed to the U.S. along with the overall quantity for the reporting period. Accurate quantity data helps FDA monitor drug availability and identify potential supply concerns.
The reporting requirements provide FDA with additional information about drug manufacturing and distribution activities. This data can help the agency monitor the availability of critical medicines, identify potential supply disruptions, and support efforts to address shortages.
Masuu US Agent assists with data collection, validation, formatting, and preparation of the required CSV files. Our team helps ensure that information such as NDC, DUNS, and drug quantity data is organized in the appropriate format for FDA submission.
Masuu US Agent provides end-to-end CARES Act reporting support, including preparation of submission data, CSV formatting, validation, and electronic submission assistance. This helps pharmaceutical companies complete applicable reporting accurately and within the required timelines.
